MUTATIONS H1069Q OF ATP7B GENE AND C282Y AND H63D OF HFE GENE IN PERSONS WITH HEPATOBILARY DISEASES OF UNDEFINED GENESIS

Haiboniuk I., Makukh H., Tyrkus M., Tretiak B., Jadzhyn L.

MEDICAL GENETICS

Scentific article

Wilson disease (WD) is an autosomal-recessive disorder of hepatocellular copper deposition caused by pathogenic variants ATP7B gene. Genetic testing of ATP7B gene is not usually used for Wilson’s disease (WD) diagnostics in Ukraine and due to the marked heterogeneity in clinical presentation the diagnosis of WD remains challenging. Hereditary hemochromatosis is an autosomal-recesive pathology coused by mutations in HFE gene. The most common mutations in this gene are H63D and C282Y. Effective therapy is developed for hemochromatosis and Wilson’s Diseases, but these pathologies still appear to be in the late stages, which is associated with nonspecific manifestations. Aim. To establish the prevalence of H1069Q mutations of the ATP7B, C282Y and H63D of the HFE gene and the contribution of hereditary hemochromatosis (HH) and Wilson’s disease (WD) into the etiology of idiopathic hepatobiliary disorders. Methods. DNA was isolated from blood samples using a modified salting out method. Detection of H63D and C282Y mutations of HFE gene was carried out using PCR and restriction fragment length polymorphism analysis, H1069Q by BI PASA analysis and detected by agarose electrophoresis. Results. 28.57% of the subjects were carriers of H63D mutation of HFE gene, 13.44% – carriers of C282Y mutation of the HFE gene but only one case of HH was confirmed. H1069Q mutation of ATP7B gene was detected in 4.0% cases which were confirmed as WD diagnosis. Such results are due to a significant higher population frequency of mutations in the HFE gene compared to ATP7B. Conclusions. The detection four times more cases of WD compared with the HH indicates a greater contribution of WD to the etiology of idiopathic hepatobiliary disorders, compared to HH.

ATP7B gene, HFE gene, Wilson’s disease, hereditary hemochromatosis, idiopathic hepatitis.

1. Kilambi R, Singh AN, Madhusudhan KS, Das P, Pal S. Choledochal cyst of the proximal cystic duct: a taxonomical and therapeutic conundrum. Ann R Coll Surg Engl. 2018;100(2):34-7. DOI: 10.1308/rcsann.2017.0201
2. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A costeffectiveness analysis. Ann. Intern. Med. 2009;152:261-9. DOI: 10.7326/0003-4819-132-4-200002150-00003
3. Cater MA, La Fontaine S, Shield K, Deal Y, Mercer JF. ATP7B mediates vesicular sequestration of copper: insight into biliary copper excretion. Gastroenterology. 2006;130:493-506. DOI: 10.1053/j.gastro.2005.10.054
4. European Association For The Study Of The Liver EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671-85. DOI: 10.1016/j.jhep.2011.11.007
5. Hanson E, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am. J. Epidemiol. 2009;158:293-6. DOI: org/10.1093/aje/154.3.193
6. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845GA (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2008;359:211-8. DOI: 10.1182/blood-2005-05-1857
7. Forbes JR, Cox DW. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins. Hum Mol Genet. 2000;9:1927-35. DOI: 10.1093/ hmg/9.13.1927
8.  Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and Analysis of Mutations in the Wilson’s Disease Gene (ATP7B): Population Frequencies, Genotype–Phenotype Correlation, and Functional Analyses. Am. J. Hum.Genet. 1997;61:317-28. DOI: 10.1086/514864
9.  Lydia K Nyasae, Michael J Schell, Ann L Hubbard. Copper Directs ATP7B to the Apical Domain of Hepatic Cells via Basolateral Endosomes. Traffic. 2014;15(12):1344-65. DOI:
10. 1111/tra.12229 10. Makukh HV, Zastavna DV, Tyrkus MYa. Pat. 32044 UA, MPK G01N33/49 (2006.01) Sposib vydilannia DNK z lejkocytiv peryferijnoi krovi, zaiavnyk DU «Instytut spadkovoi patologii NAMNU». № u200801896; zaiavl. 14.02.2008; opubl. 25.04.2008, Biul. № 8. [in Ukrainian].
11. Krumina A, Keiss J, Sondore V, Chernushenko A, Cernevska G, Zarina A, et al. From Clinical and Biochemical to Molecular Genetic Diagnosis of Wilson Disease in Latvia. Rus J of Genet. 2008;44:1195-200. DOI: 10.1134/S1022795408100086 
12. Ferenci P. Regional Distribution of Mutations of the ATP7B Gene in Patients with Wilson Disease: Impact on Genetic Testing. Hum. Genet. 2006;120:159. DOI: 10.1007/s00439-006-0202-5
13.  Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nature Genet. 1995;9:210-7. DOI: 10.1038/ng0295-210
14.  Kucinskas L, Juzenas S, Sventoraityte J. Prevalence of C282Y, H63D, and S65C mutations in hereditary HFE-hemochromatosis gene in Lithuanian population. Ann Hematol. 2012;91(4):491-5. DOI: 10.1007/s00277-011-1338-5
15.  Adler G, Clark JS, Łoniewska B, Ciechanowicz A. Prevalence of 845G>A HFE mutation in Slavic populations: an east-west linear gradient in South Slavs. Croat Med J. 2011;52(3):351-7.
16. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393-408.
17. Ferenci P. Wilson’s Disease. Clin Gastroenterol Hepatol. 2005;3(8):726-33.
18.  Myshchenko MS, Voloshyn-Gaponov IK. Sovremennye aspekty bolezni Vilsona. Mizhnarodnyj nevrologichnyj zhurnal. 2015;2(72):20-1. [in Russiаn].

«Bulletin of problems biology and medicine» Issue 1 Part 2 (149), 2019 year, 224-229 pages, index UDK 575.224.2:616.36.361-07

10.29254/2077-4214-2019-1-2-149-224-229